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Abstract
Filariasis is a tropical disease caused by the parasitic nematodes Wuchereria bancrofti and
Brugia malayi. Known inhibitors of dihydrofolate reductase (DHFR) have been previously
shown to kill Brugia malayi nematodes and to inhibit Brugia malayi DHFR (BmDHFR) at
nanomolar concentrations. These data suggest that BmDHFR is a potential target for the
treatment of filariasis. Here, protocols for cloning, expression and purification of Wuchereria
bancrofti DHFR (WbDHFR) were developed. The Uniprot entry J9F199-1 predicts a 172
amino acid protein for WbDHFR but alignment of this sequence to the previously described
BmDHFR shows that this WbDHFR sequence lacks a crucial, conserved 13 amino acid
loop. The presence of the loop in WbDHFR is supported by a noncanonical splicing event
and the loop sequence was therefore included in the gene design. Subsequently, the KM for
dihydrofolate (3.7 ± 2 μM), kcat (7.4 ± 0.6 s-1), and pH dependence of activity were deter-
mined. IC50 values of methotrexate, trimethoprim, pyrimethamine, raltitrexed, aminopterin,
(-)-epicatechin gallate, (-)-epicatechin, and vitexin were measured for WbDHFR and
BmDHFR. Methotrexate and structurally related aminopterin were found to be effective
inhibitors of WbDHFR, with an KI of 1.2 ± 0.2 nM and 2.1 ± 0.5 nM, respectively, suggesting
that repurposing of known antifolate compound may be an effective strategy to treating filari-
asis. Most compounds showed similar inhibition profiles toward both enzymes, suggesting
that the two enzymes have important similarities in their active site environments and can be
targeted with the same compound, once a successful inhibitor is identified.
Introduction
Lymphatic filariasis (elephantiasis) is a disfiguring and incapacitating disease caused by three
species of mosquito borne parasitic worms, Wuchereria bancrofti, which is responsible for 90%
of the cases, Brugia malayi and Brugia timori. This disease threatens the well-being of 947 mil-
lion people in 54 countries. Clinical manifestations include lymphedema of the limbs
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(currently approximately 15 million cases worldwide) and hydrocele (swelling of the scrotum
and penis, approximately 25 million cases) [1, 2]. Those infected with filariasis further suffer
from stigma, disabilities, and the associated economic consequences.
Dihydrofolate reductase (DHFR) is an NADPH dependent enzyme that catalyzes the for-
mation of tetrahydrofolate from dihydrofolate [3, 4]. With the exception of some prokaryotes
[5], DHFR is a ubiquitous enzyme required for folate metabolism and DNA synthesis. As
such, DHFR inhibition by “antifolates” has proven to be a successful strategy in the treatment
of cancer, bacterial infections and malaria [6, 7]. A recent Brugia malayi DHFR (BmDHFR)
3-D structural modeling and docking analysis predicted several antifolate compounds to be
effective inhibitors of the enzyme [8]. These predictions are potentially supported by findings
reported in three recent articles that show Brugia malayi nematode mobility decreased in the
presence of antifolate agents [9–11]. Moreover, folic acid reversal studies have shown that the
mobility of microfilariae decreased less when the nematodes were pre-incubated with folic
acid before treatment with the antifolate compounds. Hande and coworkers also predicted
vitexin, a compound found in passion flower, and the green tea compounds epicatechin and
(-)-epicatechin gallate to be inhibitors of BmDHFR [8].
We recently developed methods to clone, express and purify BmDHFR, and have demon-
strated its inhibition by well-known antifolates [12]. DHFR from Wuchereria bancrofti
(WbDHFR) is 96% identical to BmDHFR in amino acid sequence. We now report the develop-
ment of methods to clone, express and purify WbDHFR and compare its kinetic parameters
and inhibitor profile to those of BmDHFR. Such a comparison allows insights into whether the
amino acid differences between the two sequences have impact on kinetic parameters and
inhibitor binding.
Methods
Wuchereria bancrofti (Wb) gene sequence development
A nucleotide sequence encoding WbDHFR with an N-terminal His-6 tag was designed, syn-
thesized, and codon optimized for expression in E. coli by Genewiz. The resulting DHFR gene
sequence was subcloned into pET25b via NdeI and XhoI sites and transformed into the E. coli
LOBSTR strain for protein expression.
Expression and purification of WbDHFR
WbDHFR was expressed at 25˚C in LB media with 100 μg/mL ampicillin and induction over-
night with IPTG at 0.3 mM. The enzyme was harvested by centrifuging the E. coli mixture at
5,000 rpm for 30 min at 4˚C using a JA-10 rotor in a Beckman Avanti J-26S XP centrifuge. The
pellet was collected and supernatant discarded. This pellet was then resuspended using equili-
bration buffer (10 mM imidazole, 20 mM Na2HPO4, 300 mM NaCl, 0.1 mM DTT, at pH 7.4)
and soluble protein prepared by sonication of the wet cell paste followed by centrifugation of
the mixture using a Sorvall ST16R centrifuge at 5,000 rpm for 30 min at 4˚C. The supernatant,
rich in soluble WbDHFR, was collected and pellet discarded. His-tagged WbDHFR was puri-
fied at pH 7.4 using Ni-NTA resin. The column was washed with 100 mM imidazole wash
buffer (100 mM imidazole, 20 mM Na2HPO4, 300 mM NaCl, 0.1 mM DTT, at pH 7.4) before
being eluted with 250 mM imidazole elution buffer (250 mM imidazole, 20 mM Na2HPO4,
300 mM NaCl, 0.1 mM DTT, at pH 7.4). Protein was concentrated, and the buffer was
exchanged to 20 mM Na2HPO4, 300 mM NaCl, at pH 7.4 and the concentration was deter-
mined spectroscopically at 280 nm using the extinction coefficient 25,440 M-1cm-1.
Dihydrofolate reductase from parasitic nematode Wuchereria bancrofti
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Enzymatic activity assays
To characterize DHFR enzymatic activity, we measured absorbance at 340 nm to follow the
disappearance of DHF substrate and NADPH cofactor over time [12]. The KM of WbDHFR
for DHF was determined over a concentration range of 3.8 to 195 μM DHF, at 25˚C, in MTEN
buffer (50 mM 2-morpholinoethane sulphonic acid (MES), 25 mM Tris, 25 mM ethanolamine,
100 mM NaCl, and 1mM DTT) at pH 6.0. Initial velocity was plotted as a function of DHF
concentration using KaleidaGraph and the Michaelis-Menten equation was fitted to the data.
Catalytic activities of WbDHFR and BmDHFR were determined at various pH values (5.5–9.0)
in MTEN buffer. The MTEN buffer used for all the reported assays has essentially a constant
ionic strength at 0.15 over the pH range for which pH values were measured [13, 14]. Initial
velocity was plotted as a function of pH using Excel.
Inhibition studies
Previous computational research predicted some green tea compounds to be inhibitors of
BmDHFR [8]. Compounds (-)-epicatechin, (-)-epicatechin gallate, and vitexin were tested as
inhibitors of WbDHFR and BmDHFR. The compounds (-)-epicatechin and (-)-epicatechin
gallate were synthesized as described previously [15]. Additionally, methotrexate, trimetho-
prim, pyrimethamine, aminopterin, and raltitrexed were tested as inhibitors of WbDHFR and
BmDHFR. Stock solutions of aminopterin and raltitrexed were prepared in water and stock
solutions of the other drugs were prepared in DMSO. Control experiments were conducted to
confirm that 5% DMSO (final concentration in the experimental wells) did not affect
WbDHFR and BmDHFR activity (data not shown). The concentrations of methotrexate and
aminopterin were determined spectroscopically in 0.1 M NaOH at 302 nm using an extinction
coefficient of 22,700 M-1cm-1. Enzyme activity was measured in wells (200 μL) with 12.5 nM
WbDHFR or 40 nM BmDHFR and 100 μM NADPH and 50 μM DHF in MTEN buffer at pH
6.0 at 25˚C. Disappearance of DHF and NADPH was observed by measuring absorbance at
340 nm to measure the DHFR activity in a SpectraMax M3 microplate reader. For active inhib-
itors, IC50 curves were generated using KaleidaGraph and the IC50 values were obtained by fit-
ting the data to the Hill equation with Hill coefficient, nH. = 1. All experiments were completed
in triplicate.
To determine the mechanism of inhibition, Dixon plots were created and analyzed for the
inhibitors against WbDHFR. We determined WbDHFR activity as described above at DHF
concentrations of 2 μM, 4 μM, and 8 μM in 200 μL reaction volumes. WbDHFR (6 nM) and
100 μM NADPH cofactor were included in 1 X MTEN buffer at pH 6.0. The concentrations of
inhibitors in the assay were: methotrexate (0, 3.125 nM, 6.25 nM, and 12.5 nM), trimethoprim
(0, 10 μM, 20 μM, and 40 μM), pyrimethamine (0, 17.5 μM, 35 μM, and 70 μM), aminopterin
(0, 3 nM, 6 nM, 12 nM), and raltitrexed (0, 5 μM, 10 μM, and 20 μM). The reciprocal initial
velocities were plotted against inhibitor concentration for each substrate in Excel to create the
Dixon plots. Substrate trend-lines were extended to calculate the intersection point,–KI. Each
Dixon plot was generated in triplicate.
Results
Design and subcloning of a WbDHFR gene into a bacterial expression
vector
The Uniprot entry J9F199-1 predicts a 172 amino acid DHFR protein for Wb. Alignment of
this sequence to the previously described BmDHFR [12], however, shows that this WbDHFR
sequence lacks a crucial 13 amino acid loop that is conserved across a number of DHFR
Dihydrofolate reductase from parasitic nematode Wuchereria bancrofti
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proteins from different species (data not shown). The presence of the loop in WbDHFR can be
supported by a noncanonical splicing event (data not shown) and the loop sequence was there-
fore included in the gene design.
Expression and purification of WbDHFR
To make in vitro studies of WbDHFR possible, a protocol was developed for expression and
purification of WbDHFR using Ni-NTA resin; approximately 0.9 mg protein / 1 L of culture
was obtained (Fig 1). Attempting to purify WbDHFR using the protocol previously developed
for BmDHFR[12] resulted in protein with larger molecular weight impurities. To obtain
WbDHFR of increased purity, the imidazole concentration in the wash buffer was changed
from 25 mM to 100 mM. With this modification, we were able to successfully purify WbDHFR
(Fig 1).
Kinetic characterization of WbDHFR
Kinetic characterization of WbDHFR revealed a catalytic activity of 7.4 ± 0.6 s-1 (S.E) at pH 6.
This kcat is higher than what was found for BmDHFR, 2.2 ± 0.2 s-1 (S.E.), at the same pH value.
The KM found for DHF and WbDHFR, 3.7 ± 2.0 μM (S.D., Fig 2), is lower compared to the
KM value previously determined for BmDHFR (14.7 ± 3.6 μM); data for individual trials is
included in S1 Table [12]. The activity versus pH profile of WbDHFR was found to be similar
to that of BmDHFR (Fig 3). The different y-axis values in the two profiles indicate that
WbDHFR catalyzes the reaction faster than BmDHFR at optimal pH values.
WbDHFR and BmDHFR have similar but not identical steady-state kinetic characteristics.
Comparison of the WbDHFR and BmDHFR amino acid sequences shows eight residues to be
different (Fig 4). There are no crystal structures available for either WbDHFR or BmDHFR
and we therefore cannot directly examine the location of the residues with different sidechains.
Supporting information shows the locations of the corresponding residues superimposed on a
mouse DHFR structure (PDB# 1U70) (S1 Fig), which is the DHFR with the highest level of
sequence identity to WbDHFR and BmDHFR and an available solved structure.
Inhibition profile of WbDHFR and BmDHFR
We determined IC50 values for several known antifolate and green tea compounds against
BmDHFR and WbDHFR using the Hill Equation in KaleidaGraph (Table 1); data for individ-
ual values is shown in S2 Table [16]. The data show that methotrexate, trimethoprim, ralti-
trexed, pyrimethamine, and aminopterin inhibit WbDHFR. We did not observe inhibition for
(-)-epicatechin gallate, (-)-epicatechin, or vitexin against either WbDHFR or BmDHFR. We
used Dixon plots to experimentally investigate whether the five compounds that show inhibi-
tion based on IC50 values (Table 1) act as competitive inhibitors for WbDHFR. We plotted the
reciprocals of the initial velocity at different substrate concentrations against inhibitor concen-
trations. A linear equation was fitted to the data at each substrate concentration. The resulting
lines for all inhibitors tested crossed in the top left quadrant, indicating a competitive inhibi-
tion mechanism (Fig 5 and S3 Fig) [17]. The negative x-axis values of the point of intersection
of the lines for all pairs of individual lines were determined and the average of these values was
used to obtain the KI values listed in Table 1; each experiment was conducted in triplicate and
the standard deviations are shown and values from individual trials are shown in S3 Table.
The KI values for BmDHFR in Table 1 were obtained using the Cheng-Prusoff Equation [18].
For the two tight-binding inhibitors aminopterin and methotrexate against BmDHFR, a modi-
fication of the Cheng-Prusoff Equation for competitive inhibition for tightly bound inhibitors
was needed and we report an upper limit for the KI values [19, 20]. Inhibitor structures are
Dihydrofolate reductase from parasitic nematode Wuchereria bancrofti
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shown in supporting information (S2 Fig). Most inhibitors that were tested have similar IC50
and KI values towards both nematode homologs but pyrimethamine inhibits BmDHFR with a
KI value of 3.6 ± 1.5 μM while this drug binds WbDHFR four-times less tightly with a KI of
Fig 1. SDS-PAGE gel of WbDHFR protein after purification and concentration. Lane 1: SeeBlue Plus2 Pre-stained
Protein Standard (Novex); Lane 2: Column flow through; Lane 3: Purified WbDHFR (8.25 μg).
https://doi.org/10.1371/journal.pone.0197173.g001
Dihydrofolate reductase from parasitic nematode Wuchereria bancrofti
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15 ± 6 μM. These data suggest similarities but also subtle differences in the active sites of the
two enzymes that have only eight different amino acids in their sequences.
The IC50 value determined here for pyrimethamine for BmDHFR is different compared to
the previously determined value of the same drug against the same enzyme: 15.6 ± 6.6 μM
found now versus 109 ± 34 μM found previously [12]. To verify the drug stock concentration
in the current study, the extinction coefficient for pyrimethamine was determined to be
6.7 ± 0.8 mM-1 cm-1 at 268 nm in 1 X MTEN at pH 6.0.
Fig 2. Representative Michaelis-Menten curve. The conditions in the experimental wells (200 μL) were 100 μM NADPH, 12.4 nM WbDHFR in 1 X
MTEN buffer at pH 6.0 with DHF concentrations ranging from 0 to 195 μM. The Michaelis-Menten equation was fitted to the data using
KaleidaGraph. The Michaelis-Menten constant for DHF was determined by averaging values from fitting three separate data sets and found to be
3.7 ± 2.0 μM (S.D.).
https://doi.org/10.1371/journal.pone.0197173.g002
Dihydrofolate reductase from parasitic nematode Wuchereria bancrofti
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Fig 3. The pH based activity curve for WbDHFR (A.) and BmDHFR (B.). Enzyme concentrations in the wells were 11 nM WbDHFR and 37 nM BmDHFR. The wells
also contained 100 μM NADPH, 100 μM DHF in 1 X MTEN buffer with pH values ranging from 5.5 to 9.0.
https://doi.org/10.1371/journal.pone.0197173.g003
Fig 4. CLUSTAL alignment between Wb, Bm and mouse DHFRs. The eight amino acid differences between Wb and BmDHFR are marked with #. The 13 amino acid
region missing from the Uniprot entry and designed into the gene construct based on homology to the BmDHFR is shown in bold type and underlined. The s denote
identical residues conserved among the three sequences.
https://doi.org/10.1371/journal.pone.0197173.g004
Dihydrofolate reductase from parasitic nematode Wuchereria bancrofti
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Comparison of current data to previous computational predictions
The data agrees with some of the computational predictions by Hande and coworkers [8]; for
example, they authors predicted that trimethoprim would inhibit BmDHFR with a KI of
11 μM and we found the KI of trimethoprim to be 15 μM against BmDHFR. On the other
hand, vitexin was predicted to be a 465 nM inhibitor of BmDHFR, but in our assays we did not
observe any inhibition for vitexin against BmDHFR (Table 1). Similarly, (-)-epicatechin and
(-)-epicatechin gallate were predicted to have KI values of 76 μM and 48 μM against BmDHFR
[8] but neither compound showed any inhibitory activity against BmDHFR or WbDHFR, even
Table 1. IC50 values for compounds tested against BmDHFR and WbDHFR.
IC50 (μM) KI (μM)
Compounds BmDHFR WbDHFR BmDHFR WbDHFR
Methotrexate 0.0022 ± 0.0014 0.018 ± 0.003 <0.0005 ± 0.0003 0.0007 ± 0.0001
Trimethoprim 65 ± 13 83 ± 25 15 ± 3 5.98 ± 0.06
Raltitrexed 7.3 ± 0.2 18 ± 10 1.6 ± 0.04 2 ± 1
Pyrimethamine 16 ± 7 454 ± 37 3.6 ± 1.5 15 ± 6
Aminopterin 0.0075 ± 0.0003 0.014 ± 0.005 <0.0017 ± 0.0001 0.0021 ± 0.0005
(-)-Epicatechin gallate >1000 >1000 NA NA
(-)-Epicatechin >2500 >2500 NA NA
Vitexin >240 >240 NA NA
The values are averages from triplicates with standard deviations shown. The experiments for each compound and enzyme were conducted at pH 6.0, at room
temperature, with 100 μM NADPH, 50 μM DHF, and 40 nM BmDHFR or 12.1 nM WbDHFR in a side-by-side format, using the same solutions. The IC50 values were
obtained using the Hill Equation in KaleidaGraph. The KI values for WbDHFR were obtained from Dixon plots (Fig 5 and S3 Fig) by evaluating the initial velocity
against varying concentrations of inhibitor and DHF. The KI values for BmDHFR were obtained using the Cheng-Prusoff Equation.
https://doi.org/10.1371/journal.pone.0197173.t001
Fig 5. Representative IC50 curve (A.) and Dixon plot (B.) for trimethoprim. The inhibition experiments were carried out at 25˚C in 1 X MTEN buffer at pH 6.0. The
WbDHFR activity was assessed by monitoring the disappearance of NADPH and DHF at 340 nm over time. To obtain the IC50 (Panel A.), 100 μM NADPH, 50 μM
DHF, 12 nM WbDHFR, and trimethoprim ranging from 0.2 nM to 4.7 mM were mixed in a total volume of 200 μL. The experiment was conducted in triplicate and a
representative plot is shown. The Hill Equation was used to determine the IC50 values for trimethoprim and the average of the three values was 83 ± 25 μM. The Dixon
plot (Panel B.) was generated by evaluating the initial velocity against varying concentrations of Trimethoprim and DHF. DHF concentrations of 2 μM, 4 μM, and 8μM
and trimethoprim concentrations of 0 μM, 10 μM, 20 μM, and 40 μM were used in the assays. The velocities for each DHF concentration were plotted and the KI was
calculated to be 6 ± 0.06 μM (S.D.).
https://doi.org/10.1371/journal.pone.0197173.g005
Dihydrofolate reductase from parasitic nematode Wuchereria bancrofti
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at concentrations greater than 10 mM. We also examined other compounds that are structur-
ally related to (-)-epicatechin and (-)-epicatechin gallate and observed similar results. As the
authors state themselves, the computational predictions must be interpreted with caution due
to a lack of a crystal structure for any of the filarial parasite DHFRs.
Discussion
We found that the Uniprot entry J9F199-1 for WbDHFR lacks a crucial 13 amino acid loop.
WbDHFR, consisting of 185 amino acids (Fig 4), was successfully designed and subcloned into
the pET25b expression vector and expressed in LOBSTR E. coli cells using a modified version
of a protocol previously developed for BmDHFR. The methods that were developed to purify
active WbDHFR for in vitro studies will facilitate the testing of additional antifolate com-
pounds as potential inhibitors in the treatment of filariasis.
Well known antifolates, methotrexate and trimethoprim, were found to inhibit WbDHFR
with KI values of 1.2 ± 0.2 nM and 6 ± 0.06 μM, respectively. These KI values are significantly
different from those of methotrexate and trimethoprim against human DHFR (40 pM and
1.38 μM, respectively) [21], indicating that there are differences in the inhibitor binding of the
human DHFR compared to the parasite homologs that will likely enable discovery of selective
inhibitors. These data suggest that repurposing of known antifolate compounds can be an
effective approach for the treatment of filariasis. The expression, purification and basic kinetic
analysis of WbDHFR we publish here make it possible to test other synthetic molecules proven
to act on DHFRs from other organisms as inhibitors of WbDHFR. BmDHFR and WbDHFR
have similar kinetic and inhibition parameters; 177 of the 185 amino acid residues are con-
served (Fig 4, S1 Fig). We are currently working toward obtaining an x-ray crystal structure of
WbDHFR with an inhibitor and NADPH bound. Such a structure will further facilitate the
development of antifolate compounds in the treatment of filariasis. Most of the antifolates that
were tested, including those with lower IC50 values, inhibit the two homologs similarly, sug-
gesting the possibility that one DHFR inhibitor could be used to treat both filarial parasites.
Such an approach would be helpful in resource-poor settings where the infrastructure to deter-
mine which parasitic infection is present is not available.
Supporting information
S1 Fig. Cartoon structure of mouse DHFR (PDB # 1U70). Cofactor NADPH (left) and meth-
otrexate (right) are shown as black lines. Methotrexate is located in the inhibitor binding site.
The residue positions corresponding to those positions that have different amino acid residues
present in the BmDHFR and WbDHFR sequences are indicated as black spheres (See Fig 4 of
the research article). Numbering of these residues in the figure is based on mouse DHFR
sequence. This figure was created using Chimera.(Pettersen E.F., et. al. 2004. UCSF Chimera—
a visualization system for exploratory research and analysis. J. Comput. Chem. 13, 1605–12.)
(TIF)
S2 Fig. Structures of compounds tested as inhibitors against Wb and BmDHFR enzymes.
Structures were drawn with ChemDraw.
(TIFF)
S3 Fig. Dixon Plots for methotrexate (A.), raltitrexed (B.), pyrimethamine (C.), and ami-
nopterin (D.) for WbDHFR. All reactions were performed at 25˚C in 1 X MTEN buffer at pH
6.0. The concentration of WbDHFR and NADPH were kept constant at 6 nM and 100 μM,
respectively. DHF concentrations of 2, 4, and 8 μM were used. All experiments were per-
formed in triplicate. The plots were generated in Excel. The KI values are shown in S1 Table.
Dihydrofolate reductase from parasitic nematode Wuchereria bancrofti
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Data for trimethoprim is shown in Fig 5.
(TIF)
S1 Table. Michaelis-Menten constant KM and kcat values for WbDHFR at pH 6.0 from indi-
vidual trials.
(DOCX)
S2 Table. IC50 values for compounds tested against WbDHFR (top) and BmDHFR (bot-
tom) from each trial.
(DOCX)
S3 Table. KI values for compounds tested against WbDHFR from individual trials.
(DOCX)
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